As rates of infective endocarditis among intravenous drug users skyrocket, cardiologists are finding that treating the heart condition without addressing the disease of addiction contributes to readmissions and mortality. 

Clinical trials presented at ACC.19 flipped the script on TAVR vs. SAVR. 

The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist. 

Cardiac abnormalities stemming from preterm birth can be corrected with a three-and-a-half-month exercise program in patients’ teens and twenties, according to a drug-free trial of Canadian adults.

The addition of 2.4% hydrogen to hypoxia patients’ traditional ventilation gases improved neurologic outcomes and reduced tissue injury in a recent study of piglets, suggesting hydrogen might be a beneficial addition to therapy for babies undergoing surgery for congenital heart disease (CHD).

Boston Scientific’s LOTUS Edge Aortic Valve System was cleared by the FDA April 23 for use in high-risk surgical candidates with severe aortic stenosis.

Transsubclavian or transaxillary (TAx) access has become the preferred route for balloon-expandable TAVR when femoral access isn’t feasible, a new analysis found. Outcomes were generally favorable with TAx TAVR compared to other alternative access techniques, with the exception of higher stroke rates, researchers reported in JACC: Cardiovascular Interventions.

With CMS just months away from an updated national coverage determination for transcatheter aortic valve replacement (TAVR), a new analysis in the New England Journal of Medicine suggests the relationship between procedural volume and TAVR outcomes remains important in the United States.